AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00409773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo (unspecified)
Description: Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Study NCT05269810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Low dose
Description: 3 tablets b.i.d for 8 weeks
Study NCT05269810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Mid dose
Description: 3 tablets b.i.d for 8 weeks
Study NCT05269810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 High dose
Description: 3 tablets b.i.d for 8 weeks
Study NCT05269810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets b.i.d for 8 weeks
Study NCT02164383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 4-week starter kit of nicotine patch
Study NCT02164383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: 5 brief counseling sessions
Study NCT02164383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Games
Study NCT02390830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls Prevention
Study NCT02390830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of limitations at body function and activity levels
Study NCT01485354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring training
Description: Upper-limb training using the Armeo system for a period of 6 weeks
Study NCT00575029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: 600 mg by mouth daily
Study NCT04396756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00091949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: a thiazolidinedione drug
Study NCT00091949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT03568214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
Study NCT00638677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol
Description: Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
Study NCT00638677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol + BB12
Description: Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
Study NCT00638677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Xylitol
Description: Xylitol+BB 12 delivery with a pacifier max until 2 years
Study NCT01520506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien OneShot™ System
Description: Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
Study NCT02762916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selfmanage with the help of telemedicine program
Description: The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme
Study NCT01883258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training
Description: Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
Study NCT01883258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous moderate intensity exercise
Description: Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
Study NCT03506152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Procalcitonin
Description: Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
Study NCT02609854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Medicine (SAM)
Description: Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
Study NCT02609854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Device
Description: Inactive ultrasound device
Study NCT03660553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: 0.40 units/kg body weight
Study NCT03660553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: 0.20 units/kg body weight
Study NCT03660553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: 0.20 units/kg body weight
Study NCT03660553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: 0.20 units/kg body weight
Study NCT02794168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS203
Description: Treatment
Study NCT02794168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT00448409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax
Description: 11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
Study NCT00448409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
Study NCT00117845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (Ontak)
Description: Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
Study NCT02972463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Y
Study NCT02972463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT04530617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camostat Mesilate
Description: Tablets
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01836653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study NCT01845220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli Sprout Extract
Description: 150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
Study NCT01845220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80% acetone
Study NCT06248554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
Study NCT03675178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anerning particle
Description: Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Study NCT03675178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Study NCT02216617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere, Cisplatin, Afatinib
Study NCT01709747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Opioid for chronic pain
Study NCT01709747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable Implantable pump
Description: Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone
Study NCT01828073 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
Study NCT04327076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using robot system of endotracheal intubation and airway cleaning
Description: 1. Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~2. Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~3. During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically.
Study NCT04530617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camostat Mesilate
Description: Tablets
Study NCT04530617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemisia Annua Leaf
Description: Tea bags
Study NCT04530617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemisia Annua Leaf
Description: Tea bags
Study NCT00157677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D-dimer testing
Description: Uniform D-dimer use
Study NCT00157677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D-dimer testing
Description: Selective D-Dimer use
Study NCT02958917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
Study NCT02958917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
Study NCT02958917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo controlled
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
Study NCT02958917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
Study NCT02944149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal ligation by minilaparotomy
Description: Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
Study NCT02944149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tubal ligation by minilaparotomy
Description: Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
Study NCT03312634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene was taken orally once daily at approximately the same time each day following a meal.
Study NCT00988806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Study NCT00988806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Description: Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Study NCT00988806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Study NCT04859738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Spray
Description: Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse.
Study NCT04859738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzokain Sprey
Description: Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse.
Study NCT04859738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~In patients in the placebo group, alcohol was sprayed 60 seconds before the area where the peripheral intravenous catheter will be applied. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse.
Study NCT05202886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver from deceased donors
Description: Liver donors photographed